Oxford Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 08-12-2024
- Paid Up Capital ₹ 0.60 M
as on 08-12-2024
- Company Age 21 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
as on 08-12-2024
- Revenue -21.75%
(FY 2022)
- Profit 72.45%
(FY 2022)
- Ebitda 140.68%
(FY 2022)
- Net Worth -1.37%
(FY 2022)
- Total Assets -2.46%
(FY 2022)
About Oxford Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.60 M.
The company currently has active open charges totaling ₹2.00 M.
Satyajeet Khanolkar and Andrei Medunitsyn serve as directors at the Company.
- CIN/LLPIN
U24230MH2003PTC139562
- Company No.
139562
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Mar 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Oxford Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyajeet Khanolkar  | Director | 12-Mar-2003 | Current |
Andrei Medunitsyn  | Director | 12-Mar-2003 | Current |
Financial Performance of Oxford Lifesciences.
Oxford Lifesciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 21.75% decrease. The company also saw a substantial improvement in profitability, with a 72.45% increase in profit. The company's net worth dipped by a decrease of 1.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oxford Lifesciences?
Unlock access to Oxford Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Oxford Laboratories Private LimitedActive 24 years 10 monthsSatyajeet Khanolkar and Andrei Medunitsyn are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 13 May 2004 | ₹2.00 M | Open |
How Many Employees Work at Oxford Lifesciences?
Oxford Lifesciences has a workforce of 8 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oxford Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oxford Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
